ONC releases new health IT safety reports

Health IT safety isn’t just about protecting electronic health records (EHRs), said two new reports released by the Office of the National Coordinator for Health IT (ONC).

The two external studies summarized recent health IT safety events, identified areas where more research is needed, and collected recommendations for EHR and health IT adoption and implementation from several sources, including the Joint Commission and ONC’s own SAFER guides. In a blog post, ONC’s chief medical information officer, Andrew Gettinger, MD, said the reports highlight the complexities in managing health IT safety.

“Evidence continues to indicate that health IT safety is dependent not just on EHR systems themselves, but on a complex interplay of factors, including an institution’s leadership, culture, readiness, installation practices, training, and handling of upgrades,” Gettinger wrote. “Improving safety requires attention to all of these areas.”

Gettinger also said efforts to increase inoperability brings with the chance to improve data security, and encouraged health IT professionals to go over the recommendations collected in the second report to inform their own safety policies. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.